食管保护技术限制局部晚期非小细胞肺癌同步整合加量调强放疗与同步化疗所致放射性食管炎
研究纳入87例IIIA/B期非小细胞肺癌患者,接受根治性同步整合加量调强放疗(SIB-IMRT)与同步化疗,分为食管保护组44例与非保护组43例。食管保护组重度放射性食管炎(3级)发生率显著更低(p=0.002),营养状态更好(p=0.045),两组总生存(p=0.301)与局部区域无失败生存(p=0.871)相当。作者认为食管保护技术是限制放射性食管炎的有效且必要方法,且不损害局部控制。
要点
- 食管保护组3级放射性食管炎发生率显著低于非保护组(p=0.002)。
- 食管保护组营养状态优于非保护组(p=0.045)。
- 两组总生存(p=0.301)与局部区域无失败生存(p=0.871)无显著差异。
核心结论
- 作者认为食管保护技术是限制局部晚期非小细胞肺癌接受SIB-IMRT与同步化疗所致放射性食管炎的有效且必要方法,且不损害局部控制。
研究设计与样本
- 87例IIIA/B期非小细胞肺癌患者接受根治性SIB-IMRT与同步化疗,分为食管保护组44例与非保护组43例。
- 采用卡方检验比较两组性别、临床分期、组织学、同步化疗、放射性食管炎与营养状态,t检验比较剂量学参数,Kaplan-Meier法计算总生存与局部区域无失败生存并用log-rank检验比较。
主要发现
- 食管保护组重度放射性食管炎(3级)发生率显著低于非保护组(p=0.002)。
- 食管保护组营养状态优于非保护组(p=0.045)。
- 中位随访18个月(范围1-51个月),全部患者1年、2年、3年总生存分别为86.6%、65.4%、43.7%。
- 全部患者1年、2年局部区域无失败生存分别为78.4%、65.9%。
- 两组总生存时间(p=0.301)与局部区域无失败生存(p=0.871)相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate the incidence of radiation esophagitis (RE) and tumor local control using esophagus sparing technique in locally advanced non-small cell lung cancer (LANSCLC) treated by simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) and concurrent chemotherapy. METHODS: Eighty-seven patients with stage IIIA/B NSCLC who received definitive SIB-IMRT and concurrent chemotherapy had been divided into two groups: 1.with esophagus sparing technique; 2.without esophagus sparing technique. Chi-square test was performed to compare sex, clinical stage, histology, concurrent chemotherapy, RE and nutrition status between two groups. T-test was used to compare the dosimetric parameters. Overall survival (OS) and loco-regional failure free survival (LRFS) were calculated by the Kaplan-Meier method and compared by a log-rank test. RESULTS: There were 44 patients in the esophagus sparing group and 43 in the non-sparing group. The incidence of severe RE (Grade 3) was significantly lower in patients with esophagus sparing technique (p = 0.002). Patients in esophagus sparing group had better nutrition status (p = 0.045). With a median follow-up of 18 months (range 1-51 months), the 1-year, 2-year and 3-year OS of all the patients was 86.6, 65.4 and 43.7%. The 1-year, 2-year LRFS was 78.4, 65.9%. OS time (p = 0.301) and LRFS (p = 0.871) was comparable between two groups. CONCLUSIONS: Esophagus-sparing technique is an effective and essential method to limit RE in LANSCLC treated by SIB-IMRT and concurrent chemotherapy without compromising local control.
引用
- Ma L, Qiu B, Li Q, et al. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy. Radiat Oncol. 2018. PMID: 30016978. doi:10.1186/s13014-018-1073-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。